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Abstract
The objective of the present randomized, open-label, naturalistic 8-week study was to compare the efficacy and safety of treat-
ment with clonazepam (N = 63) and paroxetine (N = 57) in patients with panic disorder with or without agoraphobia. Efficacy 
assessment included number of panic attacks and clinician ratings of the global severity of panic disorders with the clinical 
global impression (CGI) improvement (CGI-I) and CGI severity (CGI-S) scales. Most patients were females (69.8 and 68.4% in 
the clonazepam and paroxetine groups, respectively) and age (mean ± SD) was 35.9 ± 9.6 years for the clonazepam group and 
33.7 ± 8.8 years for the paroxetine group. Treatment with clonazepam versus paroxetine resulted in fewer weekly panic attacks 
at week 4 (0.1 vs 0.5, respectively; P < 0.01), and greater clinical improvements at week 8 (CGI-I: 1.6 vs 2.9; P = 0.04). Anxiety 
severity was significantly reduced with clonazepam versus paroxetine at weeks 1 and 2, with no difference in panic disorder 
severity. Patients treated with clonazepam had fewer adverse events than patients treated with paroxetine (73 vs 95%; P = 
0.001). The most common adverse events were drowsiness/fatigue (57%), memory/concentration difficulties (24%), and sexual 
dysfunction (11%) in the clonazepam group and drowsiness/fatigue (81%), sexual dysfunction (70%), and nausea/vomiting 
(61%) in the paroxetine group. This naturalistic study confirms the efficacy and tolerability of clonazepam and paroxetine in the 
acute treatment of patients with panic disorder. 
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Panic disorder is a chronic debilitating illness character-
ized by severe, recurrent, spontaneous panic attacks with 
autonomic symptoms, with a lifetime prevalence rate of 5% 
(1). Panic disorder, both with and without agoraphobia, can 
be profoundly physically and emotionally disabling for af-
fected individuals, and is associated with substantial costs 
to society (2-5). The disease has several adverse psycho-
logical consequences, including poor general medical and 
emotional health, increased risk of alcohol abuse, marital 
and occupational dysfunction, greater use of medication, 
increased emergency room use, with up to 20% of sufferers 
attempting suicide (2).
Pharmacotherapy is effective in the treatment of panic 
disorder compared with placebo (6-8); however, it is prob-
lematic for several reasons. Despite pharmacotherapy, 
20-40% of patients with panic disorder in clinical trials 
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remain symptomatic and this proportion may be higher in 
the naturalistic setting (9). In addition, the subtype of panic 
disorder (respiratory or non-respiratory) can influence the 
response to pharmacotherapy and affect outcomes (10-
12). Furthermore, discontinuation of pharmacotherapy can 
lead to withdrawal symptoms and a significant number of 
panic disorder patients suffer relapse flowing cessation of 
treatment (13,14).
Benzodiazepines (6,8,14) and selective serotonin 
reuptake inhibitors (SSRIs) (8,15) are two drug classes 
with proven efficacy in treating panic disorder. In a meta-
analysis of 53 studies including 7725 patients with panic 
disorder who received pharmacotherapeutic treatment, the 
benzodiazepines and SSRIs showed comparable efficacy 
(7). SSRIs have been prescribed for panic disorder with 
or without agoraphobia for over a decade and are recom-
mended as first-line treatment for panic disorder on the basis 
of their favorable safety profile (16). The efficacy and safety 
profile of the SSRI paroxetine has been demonstrated in 
the treatment of panic disorder in a number of randomized 
controlled trials (17-19). However, the benzodiazepines 
remain one of the most commonly prescribed therapeutic 
options for panic disorder (20). 
Benzodiazepines are rapidly acting, effective, well 
tolerated and suitable as monotherapy (11,21) or combi-
nation therapy (22). Clonazepam also affects serotonin 
transmission (23,24) and is the only benzodiazepine on the 
market for which additional serotonergic activity has been 
shown, an action that may contribute to its ansiolytic effects 
(23-25). Benzodiazepines and SSRIs are associated with 
different adverse event (AE) profiles (6,14). When patients 
with panic disorder cannot tolerate the AEs associated with 
a particular drug class, switching to a different drug class 
can improve the safety outcomes of panic disorder (6,26). 
Accordingly, which drug to prescribe depends largely on 
considerations of AE profiles (6).
Although SSRIs and benzodiazepines have been 
shown to have comparable efficacy in the treatment of 
panic disorder in a meta-analysis (7), there have been few 
direct comparisons in clinical trials. Double-blind, placebo-
controlled studies have demonstrated the efficacy and 
safety of clonazepam and of paroxetine individually, but 
direct comparisons between these drugs have not been 
made. Therefore, the objective of this study was to com-
pare the efficacy and safety of 8 weeks of treatment with 
clonazepam and paroxetine in patients with panic disorder 
in a naturalistic setting, using a randomized, open-label 
study design. Although the open design has its limitations, 
it permits careful individual dose adaptation as is done in 
clinical practice.
Material and Methods
Study design
The study protocol was approved by the Ethics Commit-
tee of the Instituto de Psiquiatria, Universidade Federal do 
Rio de Janeiro, Rio de Janeiro, RJ, Brazil. Written informed 
consent was obtained from all patients prior to inclusion.
This was a naturalistically designed, prospective, ran-
domized, open-label study. For patients on prior anti-panic 
medication a 1-week wash-out period was employed, except 
for those taking fluoxetine for whom a 6-week washout pe-
riod was used. Patients were initially randomized to receive 
either 0.5-2 clonazepam or 10-40 mg/day paroxetine, taken 
after dinner. The planned starting dose was 0.5-1 mg/day 
clonazepam and 10 mg/day paroxetine. Maintenance doses 
of 2 mg clonazepam and 40 mg paroxetine were planned 
to be achieved at the end of the second treatment week, 
but patients were still kept in the study if these doses were 
not achieved due to AEs. For every 4 patients entering the 
trial, two were randomly assigned to clonazepam and two 
to paroxetine. Neither the patient nor the treating physician 
had any influence on the drug taken. Treatment was given 
for 8 weeks and dose adjustment was permitted according 
to the patient’s symptoms. Clonazepam and paroxetine 
were chosen for comparison since both are approved for the 
treatment of panic disorder in Brazil. Generic and branded 
versions of both drugs are available in Brazil and cost is 
generally low, which makes their relative efficacy and safety 
an important factor in the choice of treatment. 
Patients
Patients were evaluated in the Panic and Respiration 
Laboratory of the Institute of Psychiatry, Rio de Janeiro, 
Brazil. Participants were male and female patients aged 
18-60 years who met the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, text revision criteria for 
panic disorder, with or without agoraphobia, as determined 
by a structured clinical interview. Patients were also required 
to have at least two panic attacks in the week preceding 
their inclusion in the study. Patients were excluded if they 
were unable or unwilling to provide written informed consent, 
did not complete all the evaluations before study initiation, 
or if they were diagnosed with comorbidities that could af-
fect clinical evaluation including drug abuse, neurological 
disorders, or severe personality disorder.
Outcome measures
The rating was performed by independent examiners 
who were blind to the drugs under study. Demographic and 
clinical features at baseline were compared between groups. 
Efficacy parameters were recorded at baseline and at weeks 
1, 2, 4, and 8. Efficacy assessments included the number 
of panic attack and clinician ratings of the global severity 
of panic disorder using the clinical global impression (CGI) 
and severity (CGI-S) scale. Scores ranged from 1 (not at all 
ill) to 7 (extremely ill). Global change from the baseline as-
sessment was also rated with the CGI improvement (CGI-I) 
scale. Scores ranged from 1 (very much improved) to 7 (very 
much worse). Severity of anxiety was assessed using the 
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Hamilton Anxiety Rating Scale (HAMA) 14-item test.
Regarding safety parameters, a physical examination 
was performed on day 1 of treatment and at the end of the 
treatment period or at study discontinuation. Blood pres-
sure and heart rate were measured at every visit. A 12-lead 
electrocardiogram and laboratory tests (i.e., hematology, 
chemistry, urinalysis) were obtained at baseline and at 
week 8. AEs were recorded at baseline and at each defined 
time during treatment by independent examiners who were 
blind to the study drugs. AE data were collected by ask-
ing about spontaneous complaints and by a subsequent 
systematic inquiry using a list of AEs that were combined 
with the Benzodiazepine Discontinuation Symptom Scale 
(27). The severity of each AE was also recorded; multiple 
episodes of the same AE were counted only once, but they 
were rated at the greatest level of severity. 
Statistical analysis
All patients who took at least one dose were included in 
the final analysis. Patient responses were analyzed based 
on an intent to treat, last value carried forward approach. 
Appropriate parametric and non-parametric tests were 
employed; the Student t-test for independent samples were 
used for HAMA and for the number of panic attacks. The 
Cochran-Armitage χ2 test for linear trends was employed 
for CGI-I and CGI-S. The statistical analyses were two-
tailed and 5% was considered to be significant.
Results
Overall
A total of 120 patients met the inclusion criteria; 63 
were randomized to receive clonazepam and 57 to re-
ceive paroxetine. One patient in the clonazepam group 
and seven patients in the paroxetine group withdrew 
consent before the first drug intake. These patients had 
been included in the randomization process but were 
not considered in the total number of patients. Patient 
demographics and clinical characteristics were similar for 
the two groups, with no statistically significant differences 
between groups for any of the parameters studied (Table 
1). Most patients were females (69%), were educated 
at least to high school level (63%), and were employed 
(66%). Most patients included had panic disorder plus 
agoraphobia (93%) and had not received prior therapy 
(63%). The high proportion of patients suffering from 
agoraphobia was due to patients with a long history of 
panic disorder and agoraphobia often being referred to 
our institute. Of 44 patients with prior therapy, 1 patient 
in the paroxetine group had failed treatment previously 
with an SSRI and no patients in the clonazepam group 
had failed with a benzodiazepine. The mean (± SD) 
initial dose was 0.97 ± 0.1 mg/day in the clonazepam 
group and 10.5 ± 2.3 mg/day in the paroxetine group. 
At week 8, the mean dose was 1.92 ± 0.3 mg/day in the 
clonazepam group and 38.4 ± 3.7 mg/day in the paroxetine 
group. Two patients who received paroxetine and 1 patient 
who received clonazepam withdrew from the study at the 
end of the first month as a result of poor efficacy; all other 
patients participated until the end of the 8-week study.
A 1-week wash-out period was included to remove prior 
anti-panic medication. Less than 25% of the patients in each 
group were taking anti-panic medication one week before 
staring the trial (24.6% in the paroxetine group and 12.7% 
in the clonazepam group). There was no significant differ-
ence in the number of panic attacks, CGI, or AEs reported 
by these patients at screening and at baseline. 
Efficacy
After initiation of drug treatment there was a dramatic 
decrease in the number of weekly panic attacks in both 
treatment groups, which persisted over the course of the 
treatment period (Figure 1). At week 4, patients in the 
clonazepam group had significantly fewer panic attacks 
(0.1 ± 0.5 per week) than those in the paroxetine group 
(0.5 ± 0.9 per week; P < 0.01; Table 2). At week 8, patients 
experienced similarly low numbers of panic attacks with 
clonazepam and paroxetine (0.2 ± 0.6 vs 0.2 ± 0.4 per 
week, respectively; P = not significant). The two groups 
showed a similar average reduction of panic attacks over 
Table 1. Patient baseline demographics and clinical characteristics.
Clonazepam Paroxetine
Number of patients 63 57
Age [years (mean ± SD)] 35.9 ± 9.6 33.7 ± 8.8
Gender
Female 44 (69.8) 39 (68.4)
Male 19 (30.2) 18 (31.6)
Education
High school or less 25 (39.7) 20 (35.1)
College or more 38 (60.3) 37 (64.9)
Marital status
Married 33 (52.4) 29 (50.9)
Not married 30 (47.6) 28 (49.1)
Employment status
Employed 39 (61.9) 40 (70.2)
Unemployed 24 (38.1) 17 (29.8)
Diagnosis
Panic disorder without agoraphobia 4 (6.3) 5 (8.8)
Panic disorder with agoraphobia 59 (93.7) 52 (91.2)
Previous therapy
Yes 23 (36.5) 21 (36.8)
No 40 (63.5) 36 (63.2)
Weight [kg (mean ± SD)] 73.55 ± 9.04 71.7 ± 8.96
Data are reported as number of patients with percent in parenthe-
ses, unless otherwise stated.
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Figure 1. Number of panic attacks (PA) experienced by patients receiving clonazepam or paroxetine. *P < 0.05 compared to paroxetine 
(t-test).
Table 2. Summary of efficacy variables at baseline and at weeks 1, 2, 4, and 8.
Efficacy variable Clonazepam (N = 63) Paroxetine (N = 57)
Mean ± SD Range (min-max) Mean ± SD Range (min-max)
Baseline
No. of panic attacks per month 5.4 ± 2.6 3-14 5.3 ± 2.3 3-14
CGI-I - - -   -
CGI-S 4.5 ± 0.5 4-5 4.3 ± 0.5* 4-5
HAMA 11.9 ± 2.4 7-16 11.5 ± 2.7 6-16
Week 1
No. of panic attacks per week 0.8 ± 1.1 0-6 1.0 ± 1.3 0-4
CGI-I 2.2 ± 0.8 1-4 2.7 ± 1.0** 1-5
CGI-S 2.2 ± 1.1 1-5 2.5 ± 1.2 1-5
HAMA 10.0 ± 3.5 3-19 12.2 ± 4.2** 6-20
Week 2
No. of panic attacks per week 0.6 ± 1.0 0-5 0.7 ± 1.1 0-8
CGI-I 2.2 ± 1.0 1-5 2.7 ± 1.2** 1-5
CGI-S 2.1 ± 1.2 1-6 2.5 ± 1.3 1-5
HAMA 11.1 ± 3.4 5-21 12.7 ± 3.4* 6-21
Week 4
No. of panic attacks per week 0.1 ± 0.5 0-3 0.5 ± 0.9** 0-4
No. of patients with ≤1 panic attack during previous month   43 (68%) 35 (61%)
CGI-I 2.0 ± 1.1 1-4 2.2 ± 1.2 1-5
CGI-S 2.0 ± 1.0 1-4 2.2 ± 1.3 1-5
HAMA 11.8 ± 3.7 5-18 11.4 ± 4.3 5-20
Week 8
No. of panic attacks per week 0.2 ± 0.6 0-3 0.2 ± 0.4 0-1
No. of patients with ≤1 panic attack during previous month   49 (78%) 39 (68%)
CGI-I 1.6 ± 1.0 1-5 2.9 ± 1.2* 1-5
CGI-S 1.6 ± 1.0 1-5 1.9 ± 1.2 1-5
HAMA 10.5 ± 3.9 3-21 10.4 ± 3.7 3-20
CGI-I = clinical global impression - improvement; CGI-S = clinical global impression - severity; HAMA = Hamilton Anxiety Rating 
Scale. CGI-I values are related to baseline. *P < 0.05 and **P < 0.001 based on t-tests for HAMA and number of panic attacks, and on 
Cochran-Armitage tests for CGI-I and CGI-S.
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the first 8 weeks of treatment (Figure 1). The proportion of 
patients who were panic free following treatment is pre-
sented in Figure 2. At week 4, more patients who received 
clonazepam were free of panic attacks (92.06 vs 70.16%, 
respectively; P = 0.002). 
Clonazepam had a faster onset of action than parox-
etine. When CGI-I was assessed, patients treated with 
clonazepam had significantly greater improvements than 
those treated with paroxetine at week 1 (2.2 ± 0.8 vs 2.7 
± 1.0; P = 0.003) and week 2 (2.2 ± 1.0 vs 2.7 ± 1.2; P = 
0.006; Table 2). CGI-I was further reduced over the course 
of the study, with values of 1.6 ± 1.0 for clonazepam and 
2.9 ± 1.2 for paroxetine (P = 0.04) at week 8. At baseline, 
the severity of panic disorder as measured by CGI-S was 
borderline significantly higher in patients randomized to re-
ceive clonazepam versus paroxetine (4.5 ± 0.5 vs 4.3 ± 0.5; 
P = 0.02; Table 2). After 4 weeks of treatment, there was no 
Figure 2. Proportion of patients who were free of panic attacks 
following treatment with clonazepam or paroxetine. *P < 0.05 
compared to paroxetine (Fischer exact test).
Table 3. Summary of adverse events (AE) at week 8. 
Safety variable Clonazepam (N = 63) Paroxetine (N = 57) P
Before treatment† During treatment Before treatment† During treatment
Overall Overall Mild Moderate Severe Overall Overall Mild Moderate Severe
Patients with AE 40 (63.5) 46 (73.0) 37 (64.9) 54 (94.7) **
AEs
Drowsiness/fatigue 0 36 (57) 30 6 0 46 (81) 34 12 **
Sexual dysfunction  8 (13)   7 (11)   7   8 (14) 40 (70) 25 14 1 **
Memory/concentration difficulties 22 (35) 15 (24) 15 12 (21) 23 (40) 22   1  *
Nausea/vomiting 13 (21) 0   6 (11) 35 (61) 23 12 **
Appetite/weight change 0 1 (2)    1  1 (2) 31 (54) 19 12 **
Dry mouth 1 (2) 0 2 (4) 27 (47) 27 **
Excessive sweating 2 (3) 0 0 18 (32) 17   1 **
Diarrhea/constipation 0 0 0 15 (26) 15 **
Shaking/trembling/tremor 29 (46) 0 24 (42) 14 (25) 14 **
Headache 22 (35) 0 15 (21) 4 (7)  4
Derealization 0 0 0 2 (4)  2
Anxiety/irritability 35 (56) 0 34 (60) 1 (2)  1
Paresthesia 21 (33) 0 19 (33) 1 (2)  1
Metallic taste 0 1 (2)    1 0 0
Insomnia, nightmare 29 (46) 0 25 (44) 0
Weakness 20 (32)  6 (10) 6 12 (21)   7 (12)  6   1
Tachycardia/palpitations 1 (2) 0 3 (5) 0
Muscle aches/stiffness 0 0 1 (2) 0
Depersonalization 0 0 3 (5) 0
Dizziness/lightheadedness 2 (3) 0 2 (4) 0
Blurred/double vision 1 (2) 0 0 0
Tinnitus 1 (2) 0 1 (2) 0
Data are reported as number of patients with percent in parentheses. AEs were included if they were present at least once during the 
8-week treatment period, and multiple occurrences in 1 patient were only counted once, at the highest degree of severity. †AEs occur-
ring during the last 4 weeks before baseline; AEs at baseline did not differ significantly in frequency between groups. *P < 0.05, **P < 
0.001 (χ2 test).
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significant difference between groups; CGI-S was reduced 
to 2.0 ± 1.0 in the clonazepam group and to 2.2 ± 1.3 in the 
paroxetine group. At week 8, CGI-S was 1.6 ± 1.0 in the 
clonazepam group and 1.9 ± 1.2 in the paroxetine group 
(P = not significant). In agreement with CGI-I, the severity 
of anxiety measured by HAMA at week 1 was significantly 
lower in clonazepam-treated patients (10.0 ± 3.5) than in 
paroxetine-treated patients (12.2 ± 4.2; P = 0.003; Table 2). 
Significant reductions in the clonazepam group versus the 
paroxetine group were also observed at week 2 (P = 0.03), 
but not at week 4 or at the end of the study (10.5 ± 3.9 and 
10.4 ± 3.7, respectively).
Safety
No patients withdrew because of AEs. More than 60% 
of patients enrolled in the trial reported AEs at baseline, 
regardless of the study group, and these were mainly anxi-
ety, insomnia, headache, shaking/trembling, paresthesia, 
memory/concentration difficulties, nausea/vomiting, sexual 
dysfunction, and weakness (Table 3).
Patients treated with clonazepam had significantly fewer 
AEs than patients treated with paroxetine at week 8 (73.0 
versus 94.7%, respectively; P = 0.001; Table 3). The most 
common AEs in the clonazepam group were drowsiness/
fatigue (57%), memory/concentration difficulties (24%), 
and sexual dysfunction (11%). The vast majority of AEs 
in clonazepam-treated patients were of mild severity, with 
moderate severity reported for 6 cases of drowsiness/
fatigue. The most common AEs in the paroxetine group 
were drowsiness/fatigue (81%), sexual dysfunction (70%), 
and nausea/vomiting (61%). Although most AEs in the 
paroxetine group were of mild severity, there were several 
cases of moderately severe drowsiness/fatigue, sexual 
dysfunction, nausea/vomiting, and appetite/weight change. 
A severe case of sexual dysfunction was also noted with 
paroxetine. AEs that occurred significantly more frequently 
in the paroxetine group versus the clonazepam group were 
drowsiness/fatigue (P = 0.006), sexual dysfunction, nausea/
vomiting, appetite/weight change, dry mouth, excessive 
sweating, diarrhea/constipation, and shaking/trembling/
tremor (all P < 0.001). There were no clinically significant 
changes in laboratory parameters in either group during 
the study. 
Discussion
The present investigation confirms earlier studies, 
which have demonstrated the efficacy of clonazepam 
(11,12,21,28-30) and paroxetine (18,19,31,32) in separate 
trials in the treatment of panic disorder. The present study 
compares clonazepam with paroxetine using a parallel meth-
odology with the same team of health providers. There was 
a small difference in effectiveness in favor of clonazepam 
between the two treatments. As assessed by CGI-I scores, 
clonazepam was associated with significantly greater clini-
cal improvement than paroxetine at the end of the 8-week 
treatment period. Furthermore, clonazepam was associated 
with a faster response than paroxetine. Although the number 
of panic attacks experienced was similarly reduced in both 
treatment groups by week 8, both CGI-I and HAMA scores 
were significantly better in clonazepam-treated patients than 
in paroxetine-treated patients at weeks 1 and 2. The slower 
onset of action of paroxetine is consistent with other studies 
of paroxetine and other SSRIs, and is often associated with 
increased agitation and anxiety at the beginning of treatment 
(14,33). Saeki et al. (34) demonstrated that genetic and 
pharmacokinetic factors may affect the initial therapeutic 
response to paroxetine (34). Plasma concentration of parox-
etine, serotonin transporter gene-linked polymorphic region 
(5-HTTLPR) genotype, and co-morbid physical illness were 
significant factors affecting the initial pharmacotherapeutic 
effect of paroxetine in Japanese patients (34). In contrast to 
SSRIs, benzodiazepines are associated with a rapid onset 
of action (22,35). An SSRI can take 4-6 weeks to become 
entirely effective, but a benzodiazepine may be combined 
with an SSRI at the beginning of therapy to overcome this 
delay, and initial studies have confirmed the suitability of 
this approach (16,32,36). 
An original methodological feature of this trial was the 
systematic evaluation of AEs prior to as well as during 
treatment. This allowed us to differentiate drug-induced 
AEs from pre-existing drug-independent conditions, re-
vealing a completely new picture for some of the reported 
AEs. Several complaints, typically regarded as AEs, were 
already frequent before treatment and both investigational 
products were successful not only in reducing the frequency 
of panic attacks, but also some of the pre-existing panic 
attack symptoms such as anxiety, paresthesia, insomnia, 
weakness, headache, and shaking/trembling. Notably, 
clonazepam reduced the frequency of nausea/vomiting 
and memory and concentration difficulties, whereas these 
events became more frequent under paroxetine. Likewise, 
clonazepam had no effect on preexisting sexual activity, 
whereas paroxetine increased the frequency of sexual 
dysfunction. Both products were associated with drowsiness 
and/or fatigue. Whereas paroxetine was associated with 
appetite/weight change, dry mouth, excessive sweating 
and diarrhea/constipation, clonazepam did not have such 
effects. To summarize, in this short-term investigation of 
safety, almost all patients treated with paroxetine experi-
enced AEs compared with three-quarters of patients treated 
with clonazepam. Furthermore, there were more cases of 
moderately severe and severe AEs in the paroxetine group 
versus the clonazepam group. 
The AEs reported for clonazepam are typical of those 
expected from a highly potent benzodiazepine, and con-
sistent with the safety profile of clonazepam observed in 
other studies (11,22,30). The most frequently reported AEs 
were drowsiness and lapse in memory/concentration. In 
memory tests, delayed recall rather than immediate recall 
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was affected by benzodiazepine treatment, and the effect 
lasted for a short timeframe after administration (22). The 
AEs observed with paroxetine in the present analysis are 
consistent with other studies of SSRIs (37). In addition to 
the drowsiness/fatigue, sexual dysfunction and memory 
impairment that occurred or persisted with both agents, 
paroxetine treatment was commonly associated with AEs 
such as nausea/vomiting, dry mouth, excessive sweating, 
diarrhea/constipation and tremor/shaking, which were 
not experienced by any clonazepam-treated patients. In 
addition, over half of all patients who received paroxetine 
experienced appetite/weight change compared with only 
one patient treated with clonazepam.
One of the limitations of this study was the open-label 
design. Although the open design has its limitations, it al-
lows for careful individual dose adaptation and was also 
chosen to permit continuation of the study with long-term 
treatment. Our sample also does not permit generaliza-
tion of the results. The trial was conducted at a university 
research center specialized in anxiety and mood disorders. 
For example, our sample had a high percentage of high 
school or more education, which is different from the general 
Brazilian population. The flexible dose design of the study 
precludes any dose-response findings. Patients with panic 
disorder are especially sensitive to pharmacotherapy at the 
initiation of therapy, and many patients begin on half-doses 
(14). Clonazepam was started at 0.5 or 1 mg/day in the 
present study; however, all patients in both groups reached 
the full dose by 8 weeks of treatment.
The present acute study cannot address several im-
portant problems that are linked to long-term use of the 
two drugs. This issue shall be addressed in a continuation 
study lasting 3 years and followed by drug discontinuation. 
During long-term use, SSRIs may cause weight gain and 
sexual dysfunction, primarily anorgasmia and ejaculatory 
dysfunction (17,38,39), and benzodiazepine therapy in 
panic disorder may lead to abuse or misuse and physical 
dependence, and withdrawal and rebound symptoms when 
treatment is discontinued (40). Previous reports indicate a 
high level of relapse following discontinuation of panic dis-
order pharmacotherapy (6,13,14). In a study in patients with 
panic disorder who received paroxetine for 12 months, 17% 
of patients experienced one or more panic attacks during 
the 1-year follow-up period after paroxetine discontinuation 
(31). The long-term outcomes associated with this study, 
particularly relapse rates, would be of interest. A comparative 
study of longer duration would also prove valuable. Both 
clonazepam (11) and paroxetine (17,31) have been shown 
to be effective in the treatment of panic disorder over long 
follow-up periods in separate trials. In a naturalistic 3-year 
study of 67 patients with panic disorder, clonazepam had 
a sustained therapeutic effect over the entire treatment 
period (11). Similarly, paroxetine was effective when given 
over a 2-year period to 55 patients with panic disorder, with 
0.23 ± 0.2 panic attacks per week recorded at the end of 
the treatment period (31).
To conclude, this naturalistic study confirms the efficacy 
and tolerability of clonazepam and paroxetine in the acute 
treatment of patients with panic disorder, with greater clinical 
improvements, faster onset of action and a more favorable 
AE profile observed in clonazepam-treated patients. 
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